ResearcherUniversity of TrentoNo recent work listed

Natthakan Thongon

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6169-403X; OpenAlex author ID A5006068456. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2016: 1 paper

Papers 1

The GSK3β inhibitor BIS I reverts YAP-dependent EMT signature in PDAC cell lines by decreasing SMADs expression level. Co-author DOI 10.18632/oncotarget.8437 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Alessio Nencioni · 1 shared paper, 2016 · strength 0.05
- Paper The GSK3β inhibitor BIS I reverts YAP-dependent EMT signature in PDAC cell lines by decreasing SMADs expression level. DOI 10.18632/oncotarget.8437 ↗
Inga Bauer · 1 shared paper, 2016 · strength 0.05
- Paper The GSK3β inhibitor BIS I reverts YAP-dependent EMT signature in PDAC cell lines by decreasing SMADs expression level. DOI 10.18632/oncotarget.8437 ↗
Georg Feldmann · 1 shared paper, 2016 · strength 0.05
- Paper The GSK3β inhibitor BIS I reverts YAP-dependent EMT signature in PDAC cell lines by decreasing SMADs expression level. DOI 10.18632/oncotarget.8437 ↗
Alessandro Provenzani · 1 shared paper, 2016 · strength 0.05
- Paper The GSK3β inhibitor BIS I reverts YAP-dependent EMT signature in PDAC cell lines by decreasing SMADs expression level. DOI 10.18632/oncotarget.8437 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.